Full Breakdown
Trump Administration Announces Lower Medicare Drug Prices Amid Ongoing Controversy
11/30/2025, 10:39:40 AM
Overview of Negotiated Drug Prices
The Trump administration has announced a new round of negotiated prices for 15 widely used prescription drugs covered by Medicare, expected to save the federal government approximately $12 billion. These negotiations, part of the Medicare Drug Price Negotiation Program established by the Inflation Reduction Act (IRA) of 2022, will take effect in January 2027. The negotiated prices are projected to reduce costs by 44% compared to previous spending levels, with the Centers for Medicare and Medicaid Services (CMS) estimating that Medicare beneficiaries will collectively save around $685 million.
Key Drugs and Savings
Among the drugs included in this negotiation are popular medications such as Novo Nordisk's Ozempic and Wegovy, which are used for diabetes and weight loss, as well as cancer treatments like Ibrance and Xtandi. The negotiated prices for these drugs will range from 38% to 85% off their list prices. For instance, the price for Ozempic is set at $277, down from a previous list price of $950, while Wegovy will be priced at $386, a significant reduction from $1,350.
Official Statements & Responses
Health Secretary Robert F. Kennedy Jr. emphasized the administration's commitment to lowering healthcare costs, stating, “President Trump directed us to stop at nothing to lower health care costs for the American people.” CMS Administrator Mehmet Oz claimed that the current administration achieved “substantially better outcomes for taxpayers and seniors” compared to the previous year's negotiations under the Biden administration.
Criticism & Opposition
Despite the announced savings, the initiative has faced criticism from various quarters. The Pharmaceutical Research and Manufacturers of America (PhRMA) has condemned the IRA's price-setting policies, arguing that they threaten future medical innovation and could siphon $300 billion from biopharmaceutical research. Alex Schriver, a senior vice president at PhRMA, stated, “Whether it is the IRA or MFN, government price setting for medicines is the wrong policy for America.” Additionally, Democratic lawmakers have pointed out the Republican opposition to the IRA, asserting that the current savings are a direct result of Democratic efforts to empower Medicare to negotiate drug prices.
Conflicting Reports & Gaps
While the Trump administration claims significant savings, the actual out-of-pocket costs for Medicare beneficiaries remain uncertain, as individual expenses will depend on various factors, including specific drug plans and annual spending caps. The interaction between the negotiated prices under the IRA and separate agreements made by the Trump administration for certain drugs, such as the most favored nation pricing, is also unclear.
What's Next
Looking ahead, the next round of Medicare drug price negotiations is scheduled to begin in early 2026, with another 15 high-cost drugs expected to be selected for negotiation. However, changes to the IRA may allow for delays or exemptions for certain drugs, raising concerns about the future effectiveness of the negotiation program.
Verbatim Quotes
- “President Trump directed us to stop at nothing to lower health care costs for the American people,” — Robert F. Kennedy Jr., Secretary of Health and Human Services
- “Using the same process with a bolder direction, we have achieved substantially better outcomes for taxpayers and seniors in the Medicare Part D program — not the modest or even counterproductive ‘deals’ we saw before,” — Mehmet Oz, CMS Administrator
- “Alex Schriver in a statement said the “flawed policies” of the law “threaten future medical innovation by siphoning $300 billion from biopharmaceutical research.” — Alex Schriver, PhRMA
